Daraxonrasib Pill Shows Promise in Treating Pancreatic Cancer

A new drug trial reveals significant potential in combating pancreatic tumors, marking a major advancement in cancer treatment.

A
Aapla Nagpur Desk
20 Nov 2026, 3:21 PM IST · 2 min read
Source: Theguardian
Daraxonrasib Pill Shows Promise in Treating Pancreatic Cancer
KEY TAKEAWAYS
1

Daraxonrasib shows tumor shrinkage in over 60% of patients.

2

90% of trial participants experienced halted tumor growth.

3

76.6% of patients survived one year post-treatment, surpassing typical chemotherapy survival rates.

A new oral medication, daraxonrasib, has emerged as a potential game-changer in the treatment of pancreatic cancer, with trial results indicating that it can shrink tumors and, in some cases, render them undetectable. During a recent clinical trial, approximately one in twelve patients experienced a complete disappearance of their cancer, while nearly all participants saw their tumors stop growing. This trial involved 61 patients who had been diagnosed with advanced pancreatic cancer that had metastasized to other areas of the body.

Historically, pancreatic cancer has one of the lowest survival rates among common cancers, with half of diagnosed individuals succumbing within three months. The prognosis is particularly grim for those whose cancer has spread, with only about 3% surviving five years. The introduction of daraxonrasib offers a glimmer of hope, as doctors have noted that while it is not yet a cure, it may provide patients with additional time and improved quality of life.

Participants in the trial were monitored for an average of 18 months, with some showing no signs of cancer recurrence during this period. The results were promising: 90% of patients had their tumors cease growing, and over 60% experienced tumor shrinkage or complete disappearance. Notably, 76.6% of patients were alive one year after starting treatment, compared to the typical survival rate of 40-45% for those receiving standard chemotherapy.

Dr. Wungki Park, a gastrointestinal oncologist at Memorial Sloan Kettering Cancer Center, presented these findings at a recent symposium in Barcelona. He expressed optimism about the results, stating that they represent the closest approach to a cure he has witnessed, with unprecedented tumor response rates and prolonged disease control. He emphasized the significance of the median follow-up period, noting that the average time frame of 18 months without detectable disease is remarkable.

The implications of this breakthrough extend beyond pancreatic cancer, as daraxonrasib targets KRAS mutations common in various cancers. Experts believe this treatment could potentially benefit patients with other malignancies characterized by similar genetic alterations. While further research is essential, Michelle Mitchell, CEO of Cancer Research UK, highlighted the importance of these findings, calling it the most significant advancement in pancreatic cancer treatment in decades. She urged for more trials to evaluate the drug's effectiveness for broader use, particularly within the NHS, while acknowledging the ongoing challenges in improving survival rates for pancreatic cancer patients.

💬What did you think of this story?What did you think?

Read Next

Daraxonrasib Pill Offers Hope for Pancreatic Cancer